Lancet Study: Bharat Biotech on real-world study of Covaxin

The Hyderabad-based Bharat Biotech has admitted on the Lancet Infectious Diseases study on the effectiveness of COVAXIN (BBV152) against symptomatic RT-PCR, saying that the results compare favourably to the 65.2 percent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN in the general population.

"These findings are comparable to the 65.2 percent efficacy against the delta variant found in COVAXIN's controlled phase III clinical trials in the general population. COVAXIN also passes the WHO efficacy standards for COVID-19 vaccinations against the feared Delta variant, according to the findings "According to Bharat Biotech.

According to the first real-world assessment of the COVID-19 vaccine published in the Lancet Infectious Diseases journal, two doses of COVID-19 vaccine Covaxin (BBV152) are 50 percent efficacious against symptomatic COVID-19 disease.

From April 15 to May 15, researchers analysed 2,714 hospital personnel at the All India Institute of Medical Sciences (AIIMS) in Delhi who were symptomatic and completed a COVID-19 RT-PCR test. "There were 2714 symptomatic tested patients left," the research said, "of whom 1,617 tested positive for SARS-CoV-2 and 1,097 tested negative."

Lancet study: Covaxin 50-pc effective against symptomatic COVID

Bharat Biotech says, Developing Covaxin was an enormous challenge

Lancet also admitted Indian Covaxin, describes vaccine as 'highly effective'

 

- Sponsored Advert -

Most Popular

- Sponsored Advert -